SciBase Adjusts Warrant Terms Following September Rights Issue
Following a board-approved rights issue on September 3, 2026, Stockholm-based medical technology firm SciBase Holding AB has completed a mandatory recalculation of its series TO 2 warrants. The adjustment reflects the dilution and valuation shifts resulting from the recent capital raise, altering both subscription ratios and strike prices for holders.
Under the updated terms, each TO 2 warrant now entitles the holder to subscribe for 0.01 shares at a price of SEK 37.47 per share. This exercise window opens on April 3, 2029, and closes on April 17, 2029. The recalculation was triggered by the terms and conditions established during the company's April 2024 capital raise, which mandate adjustments to warrant structures following subsequent equity offerings.
Investors can review the full technical documentation regarding these adjustments and potential future share issue impacts on the company's official investor relations website. SciBase, known for its Nevisense dermatology diagnostic platform, continues to operate on the Nasdaq First North Growth Market with DNB Carnegie Investment Bank AB serving as its Certified Adviser.
Comments (0)
No comments yet. Be the first!